

CITATION REPORT

List of articles citing

PCSK9 is required for the disposal of non-acetylated intermediates of the nascent membrane protein BACE1

DOI: 10.1038/embor.2008.132
EMBO Reports, 2008, 9, 916-22.

Source: <https://exaly.com/paper-pdf/43643004/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
99	Oestrogen-modulated gene expression in the human endometrium. <i>Cellular and Molecular Life Sciences</i> , 2005 , 62, 239-50	10.3	84
98	Alzheimer disease Abeta production in the absence of S-palmitoylation-dependent targeting of BACE1 to lipid rafts. <i>Journal of Biological Chemistry</i> , 2009 , 284, 3793-803	5.4	119
97	Two endoplasmic reticulum (ER)/ER Golgi intermediate compartment-based lysine acetyltransferases post-translationally regulate BACE1 levels. <i>Journal of Biological Chemistry</i> , 2009 , 284, 2482-92	5.4	85
96	Cell biology, regulation and inhibition of beta-secretase (BACE-1). <i>FEBS Journal</i> , 2009 , 276, 1845-59	5.7	54
95	Aging and exercise affect the level of protein acetylation and SIRT1 activity in cerebellum of male rats. <i>Biogerontology</i> , 2010 , 11, 679-86	4.5	43
94	Viable mouse gene ablations that robustly alter brain A β levels are rare. <i>BMC Neuroscience</i> , 2010 , 11, 143	3.2	10
93	Altered longevity-assurance activity of p53:p44 in the mouse causes memory loss, neurodegeneration and premature death. <i>Aging Cell</i> , 2010 , 9, 174-90	9.9	59
92	PCSK9 is not involved in the degradation of LDL receptors and BACE1 in the adult mouse brain. <i>Journal of Lipid Research</i> , 2010 , 51, 2611-8	6.3	71
91	AT-1 is the ER membrane acetyl-CoA transporter and is essential for cell viability. <i>Journal of Cell Science</i> , 2010 , 123, 3378-88	5.3	68
90	Strategies for proprotein convertase subtilisin kexin 9 modulation: a perspective on recent patents. <i>Expert Opinion on Therapeutic Patents</i> , 2010 , 20, 1547-71	6.8	24
89	Quantitative proteomic analysis of PCSK9 gain of function in human hepatic HuH7 cells. <i>Journal of Proteome Research</i> , 2011 , 10, 2011-26	5.6	13
88	PCSK9: an emerging target for treatment of hypercholesterolemia. <i>Expert Opinion on Therapeutic Targets</i> , 2011 , 15, 157-68	6.4	38
87	The tale of protein lysine acetylation in the cytoplasm. <i>Journal of Biomedicine and Biotechnology</i> , 2011 , 2011, 970382		112
86	Proteomic assessment shows that many endoplasmic reticulum (ER)-resident proteins are targeted by N(epsilon)-lysine acetylation in the lumen of the organelle and predicts broad biological impact. <i>Journal of Biological Chemistry</i> , 2012 , 287, 22436-40	5.4	38
85	Proprotein convertase subtilisin/kexin type 9: from the discovery to the development of new therapies for cardiovascular diseases. <i>Scientifica</i> , 2012 , 2012, 927352	2.6	8
84	Biochemical inhibition of the acetyltransferases ATase1 and ATase2 reduces B-secretase (BACE1) levels and A β generation. <i>Journal of Biological Chemistry</i> , 2012 , 287, 8424-33	5.4	29
83	SLC33A1/AT-1 protein regulates the induction of autophagy downstream of IRE1/XBP1 pathway. <i>Journal of Biological Chemistry</i> , 2012 , 287, 29921-30	5.4	56

82	Systematic analysis of human lysine acetylation proteins and accurate prediction of human lysine acetylation through bi-relative adapted binomial score Bayes feature representation. <i>Molecular BioSystems</i> , 2012 , 8, 2964-73		57
81	βsite APP-cleaving enzyme 1 trafficking and Alzheimer's disease pathogenesis. <i>Journal of Neurochemistry</i> , 2012 , 120, 869-80	6	56
80	Lysine acetylation in the lumen of the ER: a novel and essential function under the control of the UPR. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2013 , 1833, 686-97	4.9	29
79	βSecretase: its biology as a therapeutic target in diseases. <i>Trends in Pharmacological Sciences</i> , 2013 , 34, 215-25	13.2	54
78	Proprotein convertases subtilisin/kexin type 9, an enzyme turned escort protein: hepatic and extra hepatic functions. <i>Journal of Diabetes</i> , 2013 , 5, 391-405	3.8	24
77	Novel drug approaches in development for the treatment of lipid disorders. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2013 , 121, 567-80	2.3	6
76	Characterization of proprotein convertase subtilisin/kexin type 9 (PCSK9) trafficking reveals a novel lysosomal targeting mechanism via amyloid precursor-like protein 2 (APLP2). <i>Journal of Biological Chemistry</i> , 2013 , 288, 10805-18	5.4	41
75	The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol. <i>Drug Design, Development and Therapy</i> , 2013 , 7, 1135-48	4.4	29
74	Developing BACE-1 inhibitors for FXS. <i>Frontiers in Cellular Neuroscience</i> , 2013 , 7, 77	6.1	6
73	The dual behavior of PCSK9 in the regulation of apoptosis is crucial in Alzheimer's disease progression (Review). <i>Biomedical Reports</i> , 2014 , 2, 167-171	1.8	36
72	The endoplasmic reticulum-based acetyltransferases, ATase1 and ATase2, associate with the oligosaccharyltransferase to acetylate correctly folded polypeptides. <i>Journal of Biological Chemistry</i> , 2014 , 289, 32044-32055	5.4	13
71	Living the PCSK9 adventure: from the identification of a new gene in familial hypercholesterolemia towards a potential new class of anticholesterol drugs. <i>Current Atherosclerosis Reports</i> , 2014 , 16, 439	6	72
70	Deficient import of acetyl-CoA into the ER lumen causes neurodegeneration and propensity to infections, inflammation, and cancer. <i>Journal of Neuroscience</i> , 2014 , 34, 6772-89	6.6	35
69	Proprotein convertase subtilisin/kexin type 9 (PCSK9): lessons learned from patients with hypercholesterolemia. <i>Clinical Chemistry</i> , 2014 , 60, 1380-9	5.5	27
68	Targeting PCSK9 for hypercholesterolemia. <i>Annual Review of Pharmacology and Toxicology</i> , 2014 , 54, 273-93	17.9	71
67	PCSK9 is present in human cerebrospinal fluid and is maintained at remarkably constant concentrations throughout the course of the day. <i>Lipids</i> , 2014 , 49, 445-55	1.6	30
66	PCSK9: a key modulator of cardiovascular health. <i>Circulation Research</i> , 2014 , 114, 1022-36	15.7	378
65	PCSK9 inhibition for the treatment of hypercholesterolemia: promises and emerging challenges. <i>Vascular Pharmacology</i> , 2014 , 62, 103-11	5.9	27

64	Lamotrigine Reduces β Site APP-Cleaving Enzyme 1 Protein Levels Through Induction of Autophagy. <i>Journal of Alzheimer's Disease</i> , 2015 , 46, 863-76	4.3	16
63	Role of PCSK9 beyond liver involvement. <i>Current Opinion in Lipidology</i> , 2015 , 26, 155-61	4.4	50
62	Potential of PCSK9 as a new target for the management of LDL cholesterol. <i>Research Reports in Clinical Cardiology</i> , 2015 , 73	0.1	6
61	Common Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Epitopes Mediate Multiple Routes for Internalization and Function. <i>PLoS ONE</i> , 2015 , 10, e0125127	3.7	13
60	The amyloid precursor protein (APP) intracellular domain regulates translation of p44, a short isoform of p53, through an IRES-dependent mechanism. <i>Neurobiology of Aging</i> , 2015 , 36, 2725-36	5.6	13
59	Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk. <i>Circulation</i> , 2015 , 132, 1648-66	16.7	124
58	PCSK9 Induces CD36 Degradation and Affects Long-Chain Fatty Acid Uptake and Triglyceride Metabolism in Adipocytes and in Mouse Liver. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015 , 35, 2517-25	9.4	106
57	Antilipidemic Drug Therapy Today and in the Future. <i>Handbook of Experimental Pharmacology</i> , 2016 , 233, 373-435	3.2	3
56	On the function and homeostasis of PCSK9: reciprocal interaction with LDLR and additional lipid effects. <i>Atherosclerosis</i> , 2015 , 238, 264-70	3.1	52
55	PCSK9 inhibition in LDL cholesterol reduction: genetics and therapeutic implications of very low plasma lipoprotein levels. <i>Pharmacology & Therapeutics</i> , 2015 , 145, 58-66	13.9	39
54	Proprotein convertase subtilisin / kexin 9 (PCSK9) inhibitors and the future of dyslipidemia therapy: an updated patent review (2011-2015). <i>Expert Opinion on Therapeutic Patents</i> , 2016 , 26, 1377-1392	6.8	18
53	PCSK9 inhibitors: an overview on a new promising lipid-lowering therapy. <i>Journal of Cardiovascular Medicine</i> , 2016 , 17, 237-44	1.9	5
52	Increased PCSK9 Cerebrospinal Fluid Concentrations in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017 , 55, 315-320	4.3	25
51	[PCSK9 - "missing link" in familial hypercholesterolemia : New therapeutic options in hypercholesterolemia and coronary artery disease]. <i>Herz</i> , 2016 , 41, 281-9	2.6	0
50	Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering. <i>Cardiovascular Research</i> , 2016 , 112, 429-42	9.9	83
49	Posttranslational Processing of Secretory Proteins. 2016 , 171-193		4
48	Co- and Post-Translational Protein Folding in the ER. <i>Traffic</i> , 2016 , 17, 615-38	5.7	69
47	Emerging Roles of PCSK9: More Than a One-Trick Pony. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016 , 36, 211-2	9.4	10

46	Targeting PCSK9 for therapeutic gains: Have we addressed all the concerns?. <i>Atherosclerosis</i> , 2016 , 248, 62-75	3.1	28
45	Metabolic Control. <i>Handbook of Experimental Pharmacology</i> , 2016 ,	3.2	1
44	Imbalanced cholesterol metabolism in Alzheimer's disease. <i>Clinica Chimica Acta</i> , 2016 , 456, 107-114	6.2	73
43	Hyperlipidemia-induced apoptosis of hippocampal neurons in apoE(-/-) mice may be associated with increased PCSK9 expression. <i>Molecular Medicine Reports</i> , 2017 , 15, 712-718	2.9	26
42	Lowering serum lipids via PCSK9-targeting drugs: current advances and future perspectives. <i>Acta Pharmacologica Sinica</i> , 2017 , 38, 301-311	8	14
41	Hypercholesterolemia: The role of PCSK9. <i>Archives of Biochemistry and Biophysics</i> , 2017 , 625-626, 39-53	4.1	17
40	APP, APLP2 and LRP1 interact with PCSK9 but are not required for PCSK9-mediated degradation of the LDLR in vivo. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2017 , 1862, 883-889 ⁵	5	7
39	Protein post-translational modifications: prediction tools and molecular modeling. <i>Computational and Structural Biotechnology Journal</i> , 2017 , 15, 307-319	6.8	96
38	PCSK9 Promotes oxLDL-Induced PC12 Cell Apoptosis Through the Bcl-2/Bax-Caspase 9/3 Signaling Pathway. <i>Journal of Alzheimer's Disease</i> , 2017 , 57, 723-734	4.3	13
37	PCSK9 Concentrations in Cerebrospinal Fluid Are Not Specifically Increased in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018 , 62, 1519-1525	4.3	14
36	Saquinone controls hepatic cholesterol homeostasis by the negative regulation of PCSK9 transcriptional network. <i>Scientific Reports</i> , 2018 , 8, 6737	4.9	18
35	Methylomic profiling and replication implicates deregulation of PCSK9 in alcohol use disorder. <i>Molecular Psychiatry</i> , 2018 , 23, 1900-1910	15.1	43
34	PCSK9 and neurocognitive function: Should it be still an issue after FOURIER and EBBINGHAUS results?. <i>Journal of Clinical Lipidology</i> , 2018 , 12, 1123-1132	4.9	27
33	PCSK9: From Basic Science Discoveries to Clinical Trials. <i>Circulation Research</i> , 2018 , 122, 1420-1438	15.7	115
32	Proprotein convertase subtilisin/kexin type 9 (PCSK9) in Alzheimer's disease: A genetic and proteomic multi-cohort study. <i>PLoS ONE</i> , 2019 , 14, e0220254	3.7	15
31	PCSK9 inhibition 2018: riding a new wave of coronary prevention. <i>Clinical Science</i> , 2019 , 133, 205-224	6.5	7
30	A deep learning method to more accurately recall known lysine acetylation sites. <i>BMC Bioinformatics</i> , 2019 , 20, 49	3.6	30
29	Proprotein Convertase Subtilisin/Kexin Type 9, Brain Cholesterol Homeostasis and Potential Implication for Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2019 , 11, 120	5.3	30

28	PCSK9 is Increased in Cerebrospinal Fluid of Individuals With Alcohol Use Disorder. <i>Alcoholism: Clinical and Experimental Research</i> , 2019 , 43, 1163-1169	3.7	9
27	Lipid lowering and Alzheimer disease risk: A mendelian randomization study. <i>Annals of Neurology</i> , 2020 , 87, 30-39	9.4	20
26	Role of Post-translational Modifications in Alzheimer's Disease. <i>ChemBioChem</i> , 2020 , 21, 1052-1079	3.8	12
25	Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer. <i>Nature</i> , 2020 , 588, 693-698	50.4	72
24	Lipid Transfer in Lipoprotein Metabolism and Cardiovascular Disease. <i>Advances in Experimental Medicine and Biology</i> , 2020 ,	3.6	1
23	Coming Back to Physiology: Extra Hepatic Functions of Proprotein Convertase Subtilisin/Kexin Type 9. <i>Frontiers in Physiology</i> , 2020 , 11, 598649	4.6	3
22	Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in the Brain and Relevance for Neuropsychiatric Disorders. <i>Frontiers in Neuroscience</i> , 2020 , 14, 609	5.1	22
21	Physiology and role of PCSK9 in vascular disease: Potential impact of localized PCSK9 in vascular wall. <i>Journal of Cellular Physiology</i> , 2021 , 236, 2333-2351	7	9
20	Proprotein Convertase Subtilisin/Kexin Type 9: A View beyond the Canonical Cholesterol-Lowering Impact. <i>American Journal of Pathology</i> , 2021 , 191, 1385-1397	5.8	26
19	Proprotein convertase subtilisin/kexin type 9 (PCSK9): A potential multifaceted player in cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021 , 1876, 188581	11.2	4
18	PCSK9 affects expression of key surface proteins in human pancreatic beta cells through intra- and extracellular regulatory circuits.		1
17	Translating the Knowledge of Functional Dynamics Toward Designing Inhibitors of BACE1, a Key Aspartate Protease in Alzheimer's Disease. 2017 , 171-193		1
16	Proprotein Convertase Subtilisin/Kexin-Type 9 and Lipid Metabolism. <i>Advances in Experimental Medicine and Biology</i> , 2020 , 1276, 137-156	3.6	8
15	PCSK9 Inhibitors and Neurocognitive Adverse Drug Reactions: Analysis of Individual Case Safety Reports from the Eudravigilance Database. <i>Drug Safety</i> , 2021 , 44, 337-349	5.1	10
14	The multifaceted role of lysine acetylation in cancer: prognostic biomarker and therapeutic target. <i>Oncotarget</i> , 2016 , 7, 55789-55810	3.3	53
13	Genetic Variants and Oxidative Stress in Alzheimer's Disease. <i>Current Alzheimer Research</i> , 2020 , 17, 208-223	3.3	12
12	Potential Link Between Proprotein Convertase Subtilisin/Kexin Type 9 and Alzheimer's Disease. 2018 , 1,		2
11	Identification of Novel Proteins Interacting with Proprotein Convertase Subtilisin/Kexin 9. 2020 , 3,		3

10	Lipid Anchors to Proteins. 2009 , 353-372		0
9	Identification of Proteins Interacting with PCSK9 Using a Protoarray Human Protein Microarray. 2019 , 2,		
8	PCSK9 inhibition-based therapeutic approaches: an immunotherapy perspective. <i>Current Medicinal Chemistry</i> , 2021 ,	4.3	2
7	The Emerging Roles of Intracellular PCSK9 and Their Implications in Endoplasmic Reticulum Stress and Metabolic Diseases.. <i>Metabolites</i> , 2022 , 12,	5.6	1
6	Finding New Ways How to Control BACE1.. <i>Journal of Membrane Biology</i> , 2022 , 1	2.3	
5	Table_1.DOCX. 2020 ,		
4	Proprotein convertase PCSK9 affects expression of key surface proteins in human pancreatic beta cells via intra- and extracellular regulatory circuits.. <i>Journal of Biological Chemistry</i> , 2022 , 102096	5.4	0
3	Metabolic impact of extrahepatic PCSK9 modulation: Extrahepatic PCSK9 modulation. 2022 , 1, 41-47		0
2	Recent Update on the Development of PCSK9 Inhibitors for Hypercholesterolemia Treatment. 2022 , 65, 15513-15539		1
1	Proprotein convertase subtilisin/kexin type 9 (PCSK9) in the central nervous system. 2023 , 105155		0